ReviewDrug and therapeutics bulletin2023
Managing acne vulgaris: an update.
Review in Drug and therapeutics bulletin, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- Review
- Sustained-Release Microneedles for Local Delivery of Antibacterial Peptide in Acne Therapy.Polymers · 2026Article
- Isotretinoin-Induced Hematuria in Acne Patients: Frequency, Risk Factors, and Management Recommendations from a Single-Center Study.Dermatology practical & conceptual · 2026Article
- Exploring the Toxicological Impact of Bisphenol A on Acne Vulgaris via the PLA2G2A-Arachidonic Acid Pathway.Clinical, cosmetic and investigational dermatology · 2026Article
- A 7-Week, Open-Label Study Evaluating the Efficacy and Safety of 415-nm/633-nm Phototherapy for Treating Mild-to-Moderate Acne in Adolescents and Adults.The Journal of clinical and aesthetic dermatology · 2025Article
- Genome-wide association meta-regression identifies stem cell lineage orchestration as a key driver of acne risk.medRxiv : the preprint server for health sciences · 2025Article
- Evaluation of the Percentage of Monocyte Subpopulations with TLR2 and TLR4 Expression About Selected Skin Functional Parameters in Patients with Acne Vulgaris-Cross-Sectional Study.Journal of clinical medicine · 2025Article
- Single-cell analysis reveals cellular heterogeneity, gene expression profiles, and pathway dynamics in acne vulgaris.Archives of dermatological research · 2025Article
- Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acne vulgaris is very common and can have significant negative impact on people. While sometimes a transient problem, acne may persist for many years and often leads to permanent scars or pigment changes. Guidelines unanimously advise topical treatments as first-line, although differ in recommending either topical benzoyl peroxide or topical retinoid (mainly adapalene) alone or in combination. Guidance published by the National Institute for Health and Care Excellence advises counselling patients regarding avoidance of skin irritation when starting topical treatments and promoting adherence (treatments take 6-8 weeks to work). Oral antibiotics are currently overprescribed for acne but have a role when coprescribed with a non-antibiotic topical treatment. Hormonal treatments, such as the combined contraceptive pill, are also effective and there is growing evidence for the use of spironolactone for women with persistent acne. Recent guidance from the Medicines and Healthcare products Regulatory Agency regarding isotretinoin has implications for specialist prescribing and monitoring, and increasing public awareness of potential risks of mental health problems and sexual dysfunction. Although acne is associated with psychiatric disorder, the mental health effects of isotretinoin remain controversial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.